Idiopathic Pulmonary Fibrosis Registry for Future Studies
Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis
1 other identifier
observational
13
1 country
1
Brief Summary
To establish a registry of patients for future studies of Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2008
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2008
CompletedFirst Submitted
Initial submission to the registry
December 29, 2008
CompletedFirst Posted
Study publicly available on registry
December 30, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 10, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 10, 2015
CompletedNovember 8, 2021
November 1, 2021
6.5 years
December 29, 2008
November 1, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Framework
To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated
7 + years
Eligibility Criteria
primary care clinic
You may qualify if:
- any patient referred to the Interstitial Lund Disease clinic who is undergoing evaluation and or treatment for a new diagnosis of ILD. This can include patients referred for presumed pulmonary fibrosis/interstitial pneumonitis (IPF, UIP, NSIP), sarcoidosis, hypersensitivity pneumonitis, cryptogenic organising pneumonia, drug-induced, or other idiopathic ILDs.
You may not qualify if:
- pregnancy
- inability to follow study requirements
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Ohio State University
Columbus, Ohio, 43210, United States
Biospecimen
blood serum BAL fluid lung biopsy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Clay B Marsh, MD
Ohio State University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2008
First Posted
December 30, 2008
Study Start
December 1, 2008
Primary Completion
June 10, 2015
Study Completion
June 10, 2015
Last Updated
November 8, 2021
Record last verified: 2021-11